Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Small Cell Lung Carcinoma 13Neoplasms 6Breast Neoplasms 3Advanced Solid Tumor 3Sarcoma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors 2Stomach Neoplasms 1Solid Tumors 1Sarcoma, Ewing 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Major Advanced Solid Tumors Other Than Colorectal 1Lung Neoplasms 1Leukemia 1Leiomyosarcoma 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Endometrial Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1ADVANCED SOLID TUMORS 1

Interventions

lutetium Lu 177 dotatate 3Octreotide 3pasireotide 2lanreotide 2amino-acid, glucose, and electrolyte solution 2Everolimus 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2famitinib 1copper dotatate CU-64 1arginyllysine 1Temozolomide 1Sunitinib 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1PM 01183 1Oxaliplatin 1Lutetium-177 1Lutetium 1Leucovorin 1Irinotecan 1Folfox protocol 1Fluorouracil 1E-7386 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gastro-enteropancreatic neuroendocrine tumor × PM 01183 × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡